Marshall Wace’s Nuvectis Pharma NVCT Stock Holding History

Marshall Wace’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-29,223	Closed	-$226K	–	3560
2026 Q1	$226K	Buy	+29,223	New	+$250K	﹤0.01%	2738
2025 Q4	–	Sell	-10,693	Closed	-$64.4K	–	3320
2025 Q3	$64.4K	Sell	10,693 -52,920	-83%	-$364K	﹤0.01%	2705
2025 Q2	$475K	Buy	63,613 +24,739	+64%	+$224K	﹤0.01%	2168
2025 Q1	$380K	Sell	38,874 -85,697	-69%	-$617K	﹤0.01%	2181
2024 Q4	$674K	Buy	124,571 +81,757	+191%	+$512K	﹤0.01%	1915
2024 Q3	$269K	Buy	42,814 +8,946	+26%	+$58.9K	﹤0.01%	2195
2024 Q2	$214K	Sell	33,868 -16,200	-32%	-$110K	﹤0.01%	2277
2024 Q1	$411K	Buy	50,068 +25,255	+102%	+$215K	﹤0.01%	2007
2023 Q4	$207K	Sell	24,813 -11,272	-31%	-$101K	﹤0.01%	1971
2023 Q3	$465K	Sell	36,085 -5,690	-14%	-$82.4K	﹤0.01%	1746
2023 Q2	$667K	Buy	+41,775	New	+$667K	﹤0.01%	1879

Other funds holding NVCT

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $193M AUM 233.09% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Marshall Wace's NVCT Position: Q2 2026 in Review

Marshall Wace sold out of Nuvectis Pharma (NVCT) in Q2 2026, closing a stake of 29,223 shares — an estimated $226K sold.

Marshall Wace first reported a position in NVCT in Q2 2023 and held it in 11 quarters. The position peaked at $674K in Q4 2024. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

Marshall Wace reported no remaining Nuvectis Pharma position as of Q2 2026 after selling out during the quarter.
Marshall Wace sold 29,223 Nuvectis Pharma shares in Q2 2026, an estimated $226K.
Marshall Wace first reported a position in Nuvectis Pharma in Q2 2023 and held it in 11 quarters.
Marshall Wace's Nuvectis Pharma position peaked at $674K in Q4 2024.
83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.